Health Secretary Robert F. Kennedy Jr. is a noted vaccine skeptic, and President Donald Trump has expressed concerns about ...

Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

Biotechnology company Moderna (NASDAQ:MRNA) in Q4 CY2024, but sales fell by 65.6% year on year to $966 million. On the other ...

Laura is an editor and staff writer at IFLScience. She obtained her Master's in Experimental Neuroscience from Imperial ...

One mother had detectable vaccine mRNA in both breastmilk and serum samples. The median vaccine mRNA amount in both sample types were comparable: 14ng/100ml (IQR 8-23) in serum compared to 7ng/100ml ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public skepticism (35% comfortable with technology) and challenges translating ...

A similar challenge arises at the microscopic level when lipid nanoparticles (LNPs)—the revolutionary drug delivery vehicles behind the COVID-19 vaccines—attempt to deliver mRNA to cells.

The American pharmaceutical company Moderna is developing an mRNA-based vaccine candidate for norovirus, designated as mRNA-1403. This vaccine is designed to protect against multiple norovirus ...